

10th anniversary

ICMRA brings together leaders of medicines regulatory authorities to provide strategic directions for enhanced collaboration, improved communication and approaches to jointly address common public health challenges, such as the COVID-19 pandemic.

ICMRA@10 - safeguarding public health through global strategic leadership and cooperation

MILESTONES



2013

December: ICMRA is established by 8 regulatory authorities with Health Canada (HC) as chair.



2014

August: ICMRA members [pledge](#) to support innovative solutions to counter Ebola outbreaks.

November: At the 9th Summit, ICMRA is formally adopted and projects on GMP inspections, generic assessment, capacity building, and mapping of international initiatives are endorsed.



2015

November: At the 10th Summit, website and communications strategy are presented.



2016

September: [Enhancing collaboration](#) to tackle outbreak of Zika virus disease.

October:

- [Mapping](#) of international regulatory initiatives published.
- At the 11th Summit, the UK Medicines and Healthcare Products Regulatory Authority (MHRA) is elected as ICMRA chair.



2017

October: [Agreement](#) on a framework for a project on innovation at the 12th Summit.



2019

July:

- [Call](#) for a One Health response to antimicrobial resistance across all sectors.
- Stressing the robustness of the assessment and monitoring of [biosimilar products](#).
- [Election](#) of the European Medicines Agency (EMA) as new chair.



2020

June:

- Explaining the robust scientific and independent assessment of [benefits and risks of vaccines](#) carried out by medicines regulators worldwide.
- Stressing the key characteristics of [clinical trials](#) that are most likely to generate conclusive evidence to enable the accelerated approval of medicines for COVID-19.



2021

January: ICMRA and WHO publish [a statement to help healthcare professionals increase trust and confidence of patients in COVID-19 vaccines](#).

August:

- Setting out [recommendations](#) for regulators to address the challenges linked to the use of AI.
- [Recommendations](#) to facilitate the use of track and trace systems at global level.

December:

- [Reflections](#) on remote approaches to GCP and GMP regulatory oversight during the COVID-19 pandemic.
- Stressing the need for continued focus on [COVID-19 therapeutics](#).



2022

June: Inviting industry to participate in [pilot programmes](#) focusing on post-approval changes and hybrid inspections.

July:

- EMA is [re-elected](#) as ICMRA chair.
- [Call](#) for international collaboration to integrate real-world evidence into regulatory decision making.

November: Publication of a [report](#) on successful regulatory and non-regulatory interventions to fight AMR.



2023

May: A series of workshops on various aspects of COVID-19 vaccines manufacturing, safety and efficacy was held. The 4th workshop establishes [key principles](#) for the adaptation of COVID-19 vaccines.

June: ICMRA receives [Global Award](#) for Outstanding Contribution to Health from DIA.

July: Reassuring the public on [the safety of COVID-19 vaccines](#).